EGFR and non-small cell lung carcinoma: Treatment of NSCLC with the EGFR-TKIs gefitinib and erlotinib results in the generation of a second-site mutation in the EGFR kinase domain that changes a threonine to a methionine—T790M—in at least 50% of patients.67